Clinical trial NCT01923220: Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis
Official title: An Open-Label, Randomized Study to Evaluate the Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis In Breast Cancer Patients Undergoing Radiation Therapy.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Breast Cancer
Keywords: Breast Cancer
Radiation Therapy
Radiation Dermatitis
Lead sponsor: HealOr
Sponsor class: INDUSTRY
First posted: 2013-08-15
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a single-center, open-label, randomized, prospective study evaluating the safety and efficacy of HO/02/02 20µg topically applied daily for 15 minutes (with gauze) on treatment fields vs. standard of care (SoC), Aloe Vera treatment

Detailed description: This is a single-center, open-label, randomized, prospective study evaluating the safety and efficacy of HO/02/02 20µg topically applied daily for 15 minutes (with gauze) on treatment fields vs. standard of care (SoC), Aloe Vera treatment in addition to sterile water for irrigation applied daily for 15 minutes (with gauze) on treatment fields to create the same cooling effect as in treatment arm 1. Both treatment arms 1\&2 treatments will be applied topically once daily for up to 8 weeks to reduce radiation dermatitis in up to 90 breast cancer patients undergoing adjuvant radiation therapy.

Eligibility criteria: Inclusion Criteria:

* Female patients 18 years old and above.
* Histology confirmed unilateral breast cancer following lumpectomy
* Planned to receive 50 Gy, whole breast XRT and regional lymph nodes radiation.
* ECOG performance status 0-2
* Completed Chemotherapy 3 weeks prior to XRT (if applicable)
* Patient should be available for the entire study period, and be able and willing to adhere to protocol requirements;
* Patient must sign an informed consent form prior to undergoing any study-related procedures

Exclusion Criteria:

* Known uncontrolled diabetes
* Prior radiation to breast
* Known connective tissue disorder
* Known skin disease over the treated breast
* Prior burn over treated area
* Evidence of infection or inflammation of breast to be treated.
* Receiving biological therapy or hormone therapy (other than Herceptin) during radiation treatment/study duration and 4 weeks prior to study entry.
* Pre-existing skin breakdown within the planned radiotherapy field at the time of study entry.
* Pregnancy, planned pregnancy, lactation or inadequate contraception as judged by the Investigator.
* Participation in another investigational drug or vaccine trial concurrently or within 30 days.
* Use of any other topical or systemic treatments aimed at radiation dermatitis.
* Use of a prescription or over-the-counter medication that contains hydrocortisone or any other cortisone or corticosteroid containing preparation

Primary outcomes:
measure: Number of patients using HO/02/02 20µg that developed grade 1-4 radiation dermatitis during adjuvant radiation therapy for breast cancer compared to SoC (Aloe Vera) commonly used as standard of care treatment.
timeFrame: 62 days
Secondary outcomes:
measure: Frequency and severity of adverse events reported by the patients and assessed clinically by NCI CTC v2.0
timeFrame: 62 Days
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: The Chaim Sheba Medical Center
Study officials:
affiliation: HealOr
name: Yair Alegranti
role: STUDY_DIRECTOR
References: